Amboss vs iCAD (DeepHealth)

Amboss is a medical knowledge platform used by students and clinicians worldwide — combining a continuously updated clinical library, exam-prep question banks, and point-of-care reference in one system, increasingly enhanced with AI features.

For students, it's exam infrastructure: tens of thousands of USMLE/exam-style questions with detailed explanations, adaptive study planning, and a library where any medical term links to a full article. For practicing clinicians, it's a fast bedside reference with evidence-based guidance, drug information and diagnostic support. AI features assist with search, explanation and study efficiency, layered on human-curated medical content.

Subscription…

iCAD develops AI-powered breast health solutions that help radiologists improve the early detection of breast cancer. Its ProFound Breast Health Suite uses deep learning to analyze mammograms, assess breast density, and identify suspicious findings. The platform is designed to increase diagnostic accuracy, reduce reading times, and optimize radiology workflows. iCAD solutions integrate with existing PACS and imaging systems and are used by hospitals, imaging centers, and breast screening programs worldwide. In 2025, iCAD was acquired by DeepHealth, a RadNet subsidiary, expanding DeepHealth's portfolio of AI-driven imaging technologies while retaining the iCAD brand.